Overview

A Study to Compare and Evaluate Intrahepatic cccDNA Reduction After Administrating Clevudine or Entecavir in the Chronic HBV Patients

Status:
Terminated

Trial end date:
2014-01-01

Target enrollment:

Participant gender:

Summary

This is a open, randomized, parallel study. Subjects will have Clevudine or Entecavir therapy for 48 weeks(Clevudine:Entecavir = 2:1), and subjects who have Complete Response(HBV DNA negative and ALT normal) will have follow-up period for additional 48 weeks.

Phase:

Phase 4

Details

Lead Sponsor:

Bukwang Pharmaceutical

Treatments:

Clevudine
Entecavir